Neuromodulation of Inflammation and Endothelial Function

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 158 participants.

Also called NCT05230732

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 158 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05230732
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT05230732. Randomized; quadruple masking; primary purpose treatment. Start 2022-09-01 (actual); primary completion 2027-02-27 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Neuromodulation of Inflammation and Endothelial Function
Condition
Systolic Heart Failure
Intervention (Device)
neuromodulation device
Intervention (Device)
SHAM
Lead sponsor
University of Oklahoma (class: other)
Collaborator
National Institute on Aging (NIA) (class: US National Institutes of Health)

Record details

Record id
cardio:ct-nct05230732
Content hash
01368ba3b4a65701326709fee3975d707b752d86f39b90ceea5ccfcd245845ab